4-ethynylpyridazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-ethynylpyridazine
• 英文别名: 4-Ethynyl-pyridazine
• 化学式: C₆H₄N₂
• 分子量: 104.111
• InChiKey: BEZATQMRVUALQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-ethynylpyridazine 在 copper(II) sulfate 、 sodium ascorbate 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 正丁醇 为溶剂， 反应 2.0h， 生成 4-(1-(trans-4-(4-(trifluoromethyl)benzyloxy)pyrrolidin-3-yl)-1H-1,2,3-triazol-4-yl)pyridazine
  参考文献：
  名称：

  [EN] TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DU FACTEUR DE TRANSCRIPTION À DOMAINE ASSOCIÉ TRANSCRIPTIONNEL AMÉLIORÉ (TEAD) ET LEURS UTILISATIONS

  摘要：

  Provided herein are compounds of Formula (I'), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), or Formula (VIII) and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers, such as carcinoma, sarcoma, lung cancer, thyroid cancer, skin cancer, ovarian cancer, colorectal cancer, prostate cancer, pancreatic cancer, esophageal cancer, liver cancer, breast cancer)) in a subject. Provided are methods of inhibiting a TEAD transcription factors (e.g., TEAD1, TEAD2, TEAD3, TEAD4) in a subject.

  公开号：

  WO2022232088A1
• 作为产物：
  描述：

  4-((trimethylsilyl)ethynyl)pyridazine 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 生成 4-ethynylpyridazine
  参考文献：
  名称：

  [EN] TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DU FACTEUR DE TRANSCRIPTION À DOMAINE ASSOCIÉ TRANSCRIPTIONNEL AMÉLIORÉ (TEAD) ET LEURS UTILISATIONS

  摘要：

  Provided herein are compounds of Formula (I'), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), or Formula (VIII) and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers, such as carcinoma, sarcoma, lung cancer, thyroid cancer, skin cancer, ovarian cancer, colorectal cancer, prostate cancer, pancreatic cancer, esophageal cancer, liver cancer, breast cancer)) in a subject. Provided are methods of inhibiting a TEAD transcription factors (e.g., TEAD1, TEAD2, TEAD3, TEAD4) in a subject.

  公开号：

  WO2022232088A1

文献信息

• Acetylenic Heteroaryl Compounds
  申请人：Wang Yihan

  公开号：US20130018046A1

  公开（公告）日：2013-01-17

  This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

  本发明涉及通式如下的化合物：其中变量基团如本文所定义，以及它们的制备和使用。
• WO2019241461A5
  申请人：——

  公开号：WO2019241461A5

  公开（公告）日：2022-01-14
• 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：AstraZeneca AB

  公开号：EP1768978B1

  公开（公告）日：2008-07-09
• ACETYLENIC HETEROARYL COMPOUNDS
  申请人：ARIAD PHARMACEUTICALS, INC.

  公开号：EP2023933A2

  公开（公告）日：2009-02-18
• OXAZOLIDINONES AS MODULATORS OF MGLUR5
  申请人：Bristol-Myers Squibb Company

  公开号：EP2638022B1

  公开（公告）日：2014-12-24